Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption

/by

Inflammatory bowel diseases (IBDs) are chronic, idiopathic, inflammatory, gastrointestinal disorders. The endocannabinoid system may have a role in the pathogenesis of IBD. We aimed to assess whether cannabis treatment influences endocannabinoids (eCBs) level and clinical symptoms of IBD patients.
Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

Read more

Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease

/by

For centuries, cannabis and its components have been used to manage a wide variety of symptoms associated with many illnesses. Gastrointestinal (GI) diseases are no exception in this regard. Individuals suffering from inflammatory bowel disease (IBD) are among those who have sought out the ameliorating properties of this plant. As legal limitations of its use have eased, interest has grown from both patients and their providers regarding the potential of cannabis to be used in the clinical setting.

Read more

Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians

/by

This randomized, double-blind, placebo-controlled, cross-over study was conducted to evaluate the safety and efficacy of two-weeks of nightly sublingual cannabinoid extract (ZTL-101) in treating chronic insomnia (symptoms ≥three months).

Read more

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

/by

Authors: Ester Pagano, Fabio A. Iannotti, Fabiana Piscitelli, Barbara Romano, Giuseppe Lucariello, Tommaso Venneri, Vincenzo Di Marzo, Angelo A. Izzo, Francesca Borrelli Published in Phytotherapy Research September 2020 Abstract Summary Fish oil (FO) and phytocannabinoids have received considerable attention for their intestinal anti‐inflammatory effects. We investigated whether the combination of FO with cannabigerol (CBG) and…

Read more

Activation of Cannabinoid Receptor 2 Prevents Colitis-Associated Colon Cancer through Myeloid Cell De-activation Upstream of IL-22 Production

/by

Authors: William Becker, Haider Rasheed Alrafa,Kiesha Wilson, Kathryn Miranda, Courtney Culpepper, Ioulia Chatzistamou, Guoshuai Cai, Mitzi Nagarkatti, Prakash S. Nagarkatti Published in Iscience August 2020 Abstract Summary Intestinal disequilibrium leads to inflammatory bowel disease (IBD), and chronic inflammation predisposes to oncogenesis. Antigen-presenting dendritic cells (DCs) and macrophages can tip the equilibrium toward tolerance or pathology….

Read more

Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment

/by

Authors: Viola Brugnatelli, Fabio Turco, Ulderico Freo and Gastone Zanette Published in Frontiers in Neuroscience April 2020 Introduction Irritable Bowel Syndrome (IBS) is a functional disorder characterized by abdominal pain, spasms, and altered bowel movements, either predominantly diarrhea (IBS-D), or predominantly constipation (IBS-C), or alternating between those states (Saha, 2014). In the Western world it…

Read more

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

/by

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016
—
Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read more

Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.

/by

Authors: John M. McPartland, Geoffrey W. Guy, Vincenzo Di Marzo
PLoS One, 12 March 2014
—
BACKGROUND: The “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology…

Read more

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

/by

Authors: Ethan Budd Russo
Neuroendocrinology Letters, April 2008
—
OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS:…

Read more